TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis

February 21, 2017, The Scripps Research Institute
Demyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit: Marvin 101/Wikipedia

Results from a new Phase 3 study conducted by the Celgene Corporation demonstrate that ozanimod, a drug candidate originally discovered and optimized at The Scripps Research Institute (TSRI), can reduce the frequency of multiple sclerosis relapse.

Relapsing multiple sclerosis is a form of the disease where patients experience a periodic worsening of symptoms. Sensory and motor loss of function leads to increased disability, and patients can need a cane or wheelchair. A signature of the disease is the appearance of lesions in the brain, which are linked to inflammation and can show up through MRI detection during active periods of multiple sclerosis relapse.

Ozanimod, discovered by TSRI Professors Hugh Rosen and Ed Roberts and their laboratories, acts as a sphingosine 1-phosphate 1 (S1PR1) receptor agonist—modulating S1PR1 signaling and blocking sources of inflammation. Rosen and Roberts went on to co-found Receptos, a clinical stage biopharmaceutical company that took ozanimod into Phase 1, 2 and 3 clinical trials and was then acquired by Celgene. Ozanimod is the first New Chemical Entity discovered from a starting point in the NIH Common Fund Molecular Libraries Initiative to reach and succeed in advanced clinical studies.

As reported by Celgene, results from the randomized, Phase 3, double-blind, double-dummy, active-controlled SUNBEAM study among 1,346 participants show that ozanimod met its primary endpoint in reducing annualized relapse rate (ARR) of relapsing , compared with an alternate drug treatment called weekly interferon (IFN) β-1a (Avonex).

Administered at doses of both 1 mg and 0.5 mg, ozanimod demonstrated statistically significant and clinically meaningful improvements, compared to Avonex, for the primary endpoint of ARR and the measured secondary endpoints of the number of MRI-detected lesions and the number of new or enlarging "T2" MRI lesions at after a year of treatment.

"It is exciting and rewarding to see the results of this new Phase 3 trial, which confirm the safety profile from the two-year extension data from the Phase 2 RADIANCE study and underscore ozanimod's efficacy in reducing the burden of MS symptoms on patients and their families," said Rosen. "We look forward to seeing the full study results, as well as the results from the Phase 3 study evaluating ozanimod in patients with ulcerative colitis."

Scientists involved in the trial plan to present the full Phase 3 trial results at an upcoming international scientific meeting.

Explore further: Study shows path to 'dial down' autoimmunity without compromising immune response

Related Stories

Study shows path to 'dial down' autoimmunity without compromising immune response

January 19, 2016
A new study led by scientists at The Scripps Research Institute (TSRI) shows how dangerous autoimmune responses, seen in diseases such as lupus and multiple sclerosis, might be "dialed down" without compromising the immune ...

Celgene will buy drug developer Receptos for $7.32 billion

July 14, 2015
Cancer drug maker Celgene said it will buy Receptos for $7.32 billion in cash, gaining a drug Receptos is studying as a treatment for multiple sclerosis and ulcerative colitis.

MS drug candidate also shows promise for ulcerative colitis

October 28, 2014
Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute (TSRI).

Study shows ozanimod as effective in treating ulcerative colitis

May 4, 2016
Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical ...

Study sheds light on the biology of progressive form of multiple sclerosis, suggests a new potential path for treatment

February 8, 2017
A research team led by scientists from Brigham and Women's Hospital has revealed how an FDA-approved drug works in the central nervous system in mice to suppress chronic inflammation. The drug, known as FTY720 (or Fingolimod) ...

Genentech announces favorable results for MS drug ocrelizumab

October 9, 2015
Swiss pharmaceutical company Genentech a member of the Roche Group, has released (at the European Committee for Treatment and Research in Multiple Sclerosis meeting) findings from Phase III clinical trials for its multiple ...

Recommended for you

Cesarean-born mice show altered patterns of brain development, study finds

October 15, 2018
Cesarean-born mice show altered patterns of cell death across the brain, exhibiting greater nerve cell death than vaginally delivered mice in at least one brain area, a finding by Georgia State University researchers that ...

Study points to possible new therapy for hearing loss

October 15, 2018
Researchers have taken an important step toward what may become a new approach to restore hearing loss. In a new study, out today in the European Journal of Neuroscience, scientists have been able to regrow the sensory hair ...

Scientists chase mystery of how dogs process words

October 15, 2018
When some dogs hear their owners say "squirrel," they perk up, become agitated. They may even run to a window and look out of it. But what does the word mean to the dog? Does it mean, "Pay attention, something is happening?" ...

Sugar, a 'sweet' tool to understand brain injuries

October 15, 2018
Australian researchers have developed ground-breaking new technology which could prove crucial in treating brain injuries and have multiple other applications, including testing the success of cancer therapies.

Scientists examine how neuropathic pain responds to Metformin

October 15, 2018
Scientists seeking an effective treatment for one type of chronic pain believe a ubiquitous, generic diabetes medication might solve both the discomfort and the mental deficits that go with the pain.

Abnormal vision in childhood can affect brain functions

October 13, 2018
A research team has discovered that abnormal vision in childhood can affect the development of higher-level brain areas responsible for things such as attention.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.